The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). Staphylococcus aureus is a bacterium that can be found on healthy people’s nose or skin. MRSA, or methicillin-resistant staphylococcus aureus, is a kind of staphylococcus aureus resistant to methicillin, a beta-lactam antibiotic. Methicillin is ineffective against MRSA strains. MRSA infects around 1% of the population who have staphylococcus aureus on their nose or skin. The infection affects the skin and tissues and spreads through direct skin-to-skin contact.
MRSA is spread in two out of every 100 people, according to the Centers for Disease Control and Prevention (CDC). In 2020, the number of people who were diagnosed with methicillin-resistant Staphylococcus aureus (MRSA) for the first time was significantly lower than in prior years. 2,883 cases were reported in 2020, compared to 3,657 cases in 2019, 3,669 cases in 2018, 3,579 cases in 2017, and 3,550 cases in 2016. Patients staying in long-term health care institutions for an extended period of time are a crucial component in the outbreak of MRSA infections. According to the Healthcare Cost & Utilization Project (HCUP), a collection of healthcare databases in the US, hospitalized patients are more likely than non-hospitalized patients who died from MRSA infections (4.7% vs. 2.1% respectively).
To Request a Sample of our Report on Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market: https://www.omrglobal.com/request-sample/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market
Improved detection of antibiotic-resistant bacterium strains utilizing technologically sophisticated diagnostic methods, as well as an increase in antibiotic use across the globe, are likely to propel the growth of the global MRSA antibiotic preparations market. Teixobactin, according to University of Melbourne experts, is effective against MRSA. These findings are anticipated to pave the way for the development of antibacterial medications to treat Gram-positive infections with thick cell walls that are multidrug-resistant. This will support accelerating the market growth.
Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered-
· By Drug Class
· By Route of Administration
· By Distribution Channel
• Regions covered-
· North America
· Europe
· Asia-Pacific
· Rest of the World
• Competitive Landscape: Pfizer Inc., Merck & Co. Inc, and AbbVie Inc. among others.
(Get 15% Discount on Buying this Report)
A full Report of Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market is Available @ https://www.omrglobal.com/industry-reports/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market
Global MRSA Drugs Market Report by Segment
By Drug Class
· Lipopeptide
· Oxazolidinone
· Tetracycline
· Cephalosporin
· Lipoglycopeptide
· Others
By Route of Administration
· Oral
· Parenteral
By Distribution Channel
· Online Pharmacy
· Hospital Pharmacy
· Retail Pharmacy
Global MRSA Drugs Market by Region
Regional Analysis
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
· Latin America
· Middle East & Africa
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
